Changes in cholesterol metabolism are most commonly the focus of mechanistic studies of lipids in atherosclerotic lesion development. However, it is widely appreciated that changes in both sphingolipids and phospholipids are important avenues of atherosclerosis research. The major emphasis of these studies has been on the degradation of these lipids on the surface of lipoproteins with a subsequent modification of cellular interactions.
The initiating stages of atherosclerosis are characterized by subendothelial cholesterol deposition and accumulation of leukocytes; predominantly macrophages and lymphocytes. One highly cited hypothesis for this formative phase of the disease is based on the subendothelial retention of lipoproteins [1] . It is proposed that retention of lipoproteins provides a milieu that modifies the retained material to a form that promotes leukocyte recruitment from the blood to the subendothelial space. There have been many proposed mechanisms for the retention and modification of lipoproteins that are both enzymatic and nonenzymatic. Of the enzymatic processes, one of the most frequently invoked is secreted sphingomyelinase (S-SMase). S-SMase is a product of the acid sphingomyelinase gene. Despite its optimal function occurring in acidic environments, S-SMase acts on modified lipoproteins to hydrolyze sphingomyelin to ceramide. As the lesional environment has been shown to be acidic, this enzyme may also act on native lipoproteins in the subendothelial space.
Although many studies have provided data that are consistent with a role of S-SMase, no atherosclerosis studies had been performed in mice with genetic deficiencies of this enzyme. To fill this void in knowledge, Devlin et al.
[2 ] performed conventional atherosclerosis studies in S-SMase-deficient mice that were also deficient in either apoE or LDL receptors. Deficiency of S-SMase in either background led to decreased lesion size in aortic roots, which is consistent with the response to retention hypothesis [1] . The study also took a more unconventional approach in determining whether this effect was associated with lipoprotein retention at the site of lesion formation. All the apoB-containing lipoproteins from apoEÀ/À mice were injected intravenously and traced to their arterial accumulation. Surprisingly, fluorescence was detectable throughout the entirety of lesions 18 h after lipoprotein injection. Also surprising was the profound reduction in lipoprotein retention determined by this assay with just the absence of S-SMase, despite the presence of many putative retention factors in the subendothelial space.
Another enzyme that has been of interest for many years in the atherosclerotic process has been lipoprotein-associated phospholipase A2 (Lp-PLA2). This enzyme was originally recognized as platelet-activating factor acetylhydrolase (PAF-AH). Inhibition of PAF-AH activity may potentially promote atherosclerosis. However, it was subsequently realized that the same enzyme hydrolyzed phospholipids to form products that would promote inflammation and be detrimental to cell viability. A recurring discussion on Lp-PLA2 has been whether its activity promotes or inhibits the development of atherosclerosis. The ultimate validation that an intervention has cardiovascular benefits is derived from randomized double-blinded trials that use clinically defined endpoints of cardiovascular disease and death. Although this is considered the gold standard, it is expensive and timeconsuming. Lowering plasma concentrations of LDL cholesterol is considered an acceptable surrogate by regulatory authorities for predicting benefit of cardiovascular risk. However, drugs that function independent of LDL cholesterol lowering will have to define benefit in alternative ways [3] . One index that has been commonly used is lesion size [4] . However, it is still uncertain whether size is the most important parameter, as it is generally accepted that acute cardiovascular events are precipitated by formation of an occlusive thrombus over lesions that are not necessarily highly stenotic [5] . Therefore, characteristics other than lesion size are being evaluated as an index of susceptibility to acute cardiovascular risk.
The search for an Lp-PLA2 inhibitor led to the development of darapladib. In studies using diabetic and hyperlipidemic swine, darapladib decreased lesion size in the left anterior descending coronary artery despite no change in plasma cholesterol concentrations [6] . This report emphasized darapladib-induced changes in lesion characteristics, in particular decreased size of necrotic cores that were equated with decreased susceptibility for lesions to promote acute thrombosis. The effect of this drug on facets of human atherosclerosis has been recently reported by Serruys et al. [7 ] . The primary endpoint was atheroma deformability and plasma concentrations of C-reactive protein. Although the drug was administered in doses that caused 59% inhibition of Lp-PLA2, there were no significant effects on these primary endpoints. Several secondary endpoints were also not significantly changed by the drug including atherosclerotic lesion size and several biomarkers, including IL-6, myeloperoxidase, ICAM-1, oxidized lipoprotein, and MMP-9. An endpoint that was significantly reduced by darapladib was the size of the necrotic core as defined by intravascular ultrasound-based radiofrequency analysis. Therefore, one parameter of lesion formation was altered, as determined by this imaging technique, although we currently do not have the knowledge to extrapolate this finding to changes in acute cardiovascular diseases.
This study reflects the current dilemma in clinical atherosclerosis research as to which characteristics to measure in lesions that will have the best predictive value for the onset of acute clinical symptoms of atherosclerosis. The value of these measurements to the prevention of onset and severity of symptoms remains to be validated. Irrespective of this dilemma, these recent experimental and clinical approaches show that the alteration of sphingolipids and phospholipids has consequences on lesion formation.
References and recommended reading
Papers of particular interest, published within the annual period of review, have been highlighted as:
of special interest of outstanding interest receptor: a novel molecular link between hyperlipidemia, weight gain, and atherosclerosis in mice. J Biol Chem 2008; 283:25650-25659. The lipolysis stimulated lipoprotein receptor was discovered over a decade ago, although its function has remains unclear. This study demonstrated that mice with a heterozygous deficiency of this receptor had a great susceptibility to diet-induced hyperlipidemia and weight gain.
